Product
SH-1028
1 clinical trial
1 indication
Indication
Lung CancerClinical trial
A Phase III, Double-blind, Randomised Study of SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With Sensitizing EGFR MutationsStatus: Recruiting, Estimated PCD: 2028-02-01